Cargando…
Clinical outcomes of EGFR +/ METamp+ vs. EGFR +/ METamp‐ untreated patients with advanced non‐small cell lung cancer
BACKGROUND: MET dysregulation has been implicated in the development of primary and secondary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. However, the clinicopathological characteristics and outcomes of patients harboring EGFR‐sensitive mutations and de novo MET amplifications still...
Autores principales: | Peng, Kai‐Cheng, Su, Jun‐Wei, Xie, Zhi, Wang, Han‐Min, Fang, Mei‐Mei, Li, Wen‐Feng, Chen, Yu‐Qing, Guan, Xu‐Hui, Su, Jian, Yan, Hong‐Hong, Zhang, Xu‐Chao, Tu, Hai‐Yan, Zhou, Qing, Chen, Hua‐Jun, Wu, Yi‐Long, Yang, Jin‐Ji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161327/ https://www.ncbi.nlm.nih.gov/pubmed/35437920 http://dx.doi.org/10.1111/1759-7714.14429 |
Ejemplares similares
-
MetAmp: combining amplicon data from multiple markers for OTU analysis
por: Zhbannikov, Ilya Y., et al.
Publicado: (2015) -
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016) -
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
por: Zhou, Qing, et al.
Publicado: (2016) -
Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023) -
Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer
por: Yin, Zi-Jun, et al.
Publicado: (2018)